Bemcentinib Completed Phase 2 Trials for Coronavirus Disease 2019 (COVID‑19) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04890509A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients